Akademik Veri Yönetim Sistemi
INDIAN JOURNAL OF DERMATOLOGY, cilt.71, sa.1, ss.24-29, 2026 (SCI-Expanded, Scopus)
Background:Diverse biological therapies have become increasingly prevalent in recent years in the treatment of psoriasis. However, current guidelines continue to recommend non-biological systemic treatments. Real-life data on the survival of acitretin and methotrexate are limited. It is important to determine the appropriate patient candidates before treatment and to determine the factors affecting survival to increase treatment compliance.Aims and Objectives:This study aimed to calculate the estimated survival and 1-, 2-, 3-, 5-year survival rates of acitretin and methotrexate and to determine the factors affecting survival. Other purposes include evaluating reasons for treatment cessation, and adverse effects.Materials and Methods:Our retrospective study, conducted at a single centre, included 364 adult patients diagnosed with psoriasis who had received at least one of the acitretin or methotrexate and had at least two visit records. The data were obtained from patient records. Response to treatment in the third month, adverse effects, and reasons for treatment discontinuation were recorded. Survival analysis was performed using the Kaplan-Meier method. Log-rank tests and Cox regression analyses were used to assess the predictive factors for survival. P <0.05 was considered significant.Results:A total of 437 treatment courses of 364 patients were evaluated. The median follow-up was 39.5 (21.00-64.75) months. The median survival was calculated as 14 months for acitretin and 20 months for methotrexate. One-year drug survival rates for acitretin and methotrexate were 49.5% and 62.7%, respectively. Treatment response was the most important determinant of drug survival for both medications, whereas advancing age and arthritis had a positive effect on methotrexate survival.Conclusion:Survival rates of acitretin and methotrexate were generally low in practice compared with published data on biological treatments, but as a response to treatment increased, the survival of both drugs improved. Better strategies need to be developed to increase treatment response and survival.